Podcasts about Sunitinib

Cancer medication

  • 27PODCASTS
  • 57EPISODES
  • 11mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jan 22, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Sunitinib

Latest podcast episodes about Sunitinib

ASCO Daily News
What's New in Prostate Cancer, RCC, and mUC at GU24

ASCO Daily News

Play Episode Listen Later Jan 22, 2024 25:10


Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ccRCC, and a compelling real-world retrospective study in mUC of patients with FGFR2 and FGFR3 mutations. TRANSCRIPT Dr. Neeraj Agarwal: Hello, everyone, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of ASCO Daily News. I am delighted to welcome Dr. Jeanny Aragon-Ching, a genitourinary oncologist and the clinical program director of Genitourinary Cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing key posters and oral abstracts that will be featured at the 2024 ASCO Genitourinary Cancer Symposium, which is celebrating 20 years of evolution in GU oncology this year.  You will find our full disclosures in the transcript of this podcast, and disclosures of all guests on the podcast at asco.org/DNpod.  Jeanny, it's great to have you on the podcast today to highlight some key abstracts for our listeners ahead of the GU meeting. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. It's an honor to be here. Dr. Neeraj Agarwal: Jeanny, as you know, this year we are celebrating the 20th anniversary of the ASCO GU Cancers Symposium, and judging from this year's abstracts, it's clear that this meeting continues to play a major role in advancing GU cancer research. Dr. Jeanny Aragon-Ching: Indeed, Neeraj. This year's abstracts reflect the important strides we have made in GU cancers. So, let's start with the prostate cancer abstracts. What is your takeaway from Abstract 19 on BRCAAway, which will be presented by Dr. Maha Hussein, and of which you are a co-author? As our listeners know, several PARP inhibitor combinations with second-generation androgen receptor pathway inhibitors, or ARPIs, have recently been approved as first-line treatment for patients with metastatic castrate-resistant prostate cancer, or metastatic CRPC, and the question of sequencing PARP inhibitors and ARPIs instead of combining them has emerged. From that perspective, the results of the BRCAAway trial are very important. Can you tell us a little bit more about this abstract, Neeraj?  Dr. Neeraj Agarwal: I totally agree with you, Jeanny. The BRCAAway study attempts to answer the crucial questions regarding sequencing versus upfront combination of therapies in the mCRPC setting. It is a phase 2 trial of abiraterone versus olaparib versus abiraterone with olaparib in patients with mCRPC harboring homologous recombination repair mutations. Enrolled patients had mCRPC disease and no prior exposure to PARP inhibitors or ARPIs or chemotherapy in the mCRPC setting and had BRCA1 or BRCA2 or ATM mutations. As previously mentioned, these patients were randomized to 3 arms: abiraterone monotherapy at 1000 milligrams once daily, or olaparib monotherapy at 300 milligrams twice daily, or the combination of abiraterone and olaparib. The primary endpoint was progression-free survival per RECIST 1.1 or Prostate Cancer Working Group 3-based criteria or clinical assessment or death, so, whichever occurred first was deemed to be progression.   Secondary endpoints included measurable disease response rates, PSA response rate, and toxicity. This was a relatively small trial with 21 patients in the combination arm, 19 patients in the abiraterone monotherapy arm, and 21 patients in the olaparib monotherapy arm. It should be noted that 26% of patients had received docetaxel chemotherapy in the hormone-sensitive setting, and only 3% of patients had any prior exposure to an ARPI, and these were darolutamide or enzalutamide or in the non-metastatic CRPC setting.  The results are very interesting. The median progression-free survival was 39 months in the combination arm, while it was 8.4 months in the abiraterone arm and 14 months in the olaparib arm. An important finding that I would like to highlight is that crossover was also allowed in the monotherapy arms. Of the 19 patients receiving abiraterone, 8 crossed over to receive olaparib, and of the 21 patients receiving olaparib, 8 crossed over to the abiraterone arm. The median PFS from randomization was 16 months in both groups of patients who received abiraterone followed by olaparib or those who received olaparib followed by abiraterone. This is striking when compared to 39 months in patients who started therapy with the combination therapy of abiraterone with olaparib. Dr. Jeanny Aragon-Ching: Thank you so much for that wonderful summary, Neeraj. So the key message from this abstract is that combining olaparib and abiraterone upfront seems to be associated with improvement in PFS compared to just sequencing those agents. Dr. Neeraj Agarwal: Exactly, Jeanny. I would like to add that these results are even more important given that in real-world practice, only half of the patients with mCRPC receive a second-line treatment. Based on these results, upfront intensification with a combination of an ARPI plus a PARP inhibitor in the first-line mCRPC setting seems to have superior efficacy compared to sequencing of these agents. Dr. Jeanny Aragon-Ching: Thank you so much. Now, moving on to a different setting in prostate cancer, there were a couple of abstracts assessing transperineal biopsy compared to the conventional transrectal biopsy for the detection of prostate cancer. So let's start with Abstract 261. Neeraj, can you tell us a little bit more about this abstract? Dr. Neeraj Agarwal: Sure, Jeanny. So, in Abstract 261 titled "Randomized Trial of Transperineal versus Transrectal Prostate Biopsy to Prevent Infection Complications," Dr. Jim Hugh and colleagues led a multicenter randomized trial comparing these 2 approaches, so, transperineal biopsy without antibiotic prophylaxis with transrectal biopsy with targeted prophylaxis in patients with suspected prostate cancer. The primary outcome was post-biopsy infection. Among the 567 participants included in the intention-to-treat analysis, no infection was reported with the transperineal approach, while 4 were detected with the transrectal approach, with a p-value of 0.059. The rates of other complications, such as urinary retention and significant bleeding, were very low and similar in both groups. The investigators also found that detection of clinically significant cancer was similar between the 2 techniques and concluded that the transperineal approach is more likely to reduce the risk of infection without antibiotic prophylaxis. Dr. Jeanny Aragon-Ching: So the key takeaway from this abstract sounds like office-based transperineal biopsy is well-tolerated and does not compromise cancer detection, along with better antibiotic stewardship and health care cost benefits.  Moving on to Abstract 273, also comparing these two approaches, what would be your key takeaway message, Neeraj?  Dr. Neeraj Agarwal: In this Abstract 273, titled "Difference in High-Risk Prostate Cancer Detection between Transrectal and Transperineal Approaches," Dr. Semko and colleagues found that the transperineal biopsy based on MRI fusion techniques was also characterized by a higher possibility of detecting high-risk prostate cancer and other risk factors as well, such as perineural and lymphovascular invasion or the presence of cribriform pattern, compared to the conventional transrectal method. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So we can see that the transperineal approach is gaining more importance and could be associated with more benefits compared to the conventional methods.   Let's now switch gears to kidney cancer, Neeraj. Dr. Neeraj Agarwal: Sure, Jeanny. Let's start by highlighting Abstract 361, which discusses patient-reported outcomes of the LITESPARK-005 study. So what can you tell us about this abstract, Jeanny?  Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So as a reminder to our listeners, based on the LITESPARK-005 trial, it was a Phase 3 trial looking at belzutifan, which is an inhibitor of hypoxia inducible factor 2 alpha or I'll just call HIF-2 alpha for short, was very recently approved by the FDA as a second-line treatment option for patients with advanced or metastatic clear cell renal cell carcinoma after prior progression on immune checkpoint and antiangiogenic therapies. The title of Abstract 361 is "Belzutifan versus Everolimus in Patients with Previously Treated Advanced RCC: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study," and this will be presented by Dr. Tom Pells at the meeting. At a median follow-up of 25.7 months, the median duration of treatment with belzutifan was 7.6 months, while it was only 3.9 months with everolimus. At the time of data cutoff date for the second interim analysis, 22.6% of patients remained on belzutifan while only 5% remained on everolimus. In the quality of life questionnaires, the time of deterioration to various quality of life scores, as assessed by standardized scales, was significantly longer in patients randomized to the belzutifan arm compared to those in the everolimus arm. Also, patients in the everolimus arm had worse physical functioning scores. Dr. Neeraj Agarwal: Yes, Jeanny. In addition to the improved outcomes associated with belzutifan, patient-reported outcomes indicate better disease-specific symptoms and better quality of life among patients treated with belzutifan compared to everolimus. This is great news for patients with advanced renal cell carcinoma.  Now, Jeanny, can you please tell us about the two abstracts that reported longer follow-up of CheckMate 9ER and CheckMate 214 trials in untreated patients with advanced or metastatic renal cell carcinoma? Dr. Jeanny Aragon-Ching: Yes, Neeraj. So you are referring to Abstracts 362 and 363. Let's start with Abstract 362. This abstract reports the results after a median follow-up of 55 months in the CheckMate 9ER trial, comparing the combination of nivolumab and cabozantinib to sunitinib in patients with advanced RCC without any prior treatment, so first-line therapy. The primary endpoint was PFS per RECIST 1.1 as assessed by an independent central review. So there were key secondary outcomes including overall survival (OS), objective response rates, and safety. Consistent with prior analysis at a median follow-up time of 18.1 and 44 months, the combination of nivolumab and cabozantinib at a median follow up of 55.6 months continues to show a significant reduction in the risk of progression or death by 42% and in the risk of death by 23% compared to sunitinib.  Dr. Neeraj Agarwal: And Jeanny, what can you tell us about the efficacy results of this combination by IMDC risk categories? Dr. Jeanny Aragon-Ching: Similar to prior results in patients with intermediate to poor risk IMDC risk category, the combination treatment maintained significant efficacy and reduced the risk of progression or death by 44% and the risk of death by 27%. To put it simply, the update now shows a 15-month improvement in overall survival with the cabozantinib-nivolumab combination compared to sunitinib, which is amazing. Also, in patients with favorable IMDC risk group, which represented truly a small number of patients in the trial, there was a strong trend for improvement of outcomes as well. I would like to point out that no new safety concerns were identified. Dr. Neeraj Agarwal: So, it looks like the key message from this abstract is that with longer follow-up, the combination of nivolumab and cabozantinib maintains a meaningful long-term efficacy benefit over sunitinib, supporting its use for newly diagnosed patients with advanced or metastatic renal cell carcinoma.   Let's move on to Abstract 363, which compares nivolumab with ipilimumab to sunitinib in first-line advanced renal cell carcinoma. What would you like to tell us about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Yes, Neeraj. The title of this abstract is "Nivolumab plus Ipilimumab versus Sunitinib for the First-Line Treatment of Advanced RCC: Long-Term Follow-Up Data from the Phase 3 CheckMate 214 Trial." In this abstract, Dr. Tannir and colleagues report outcomes with the longest median follow-up in first-line advanced RCC setting for any clinical trial. So the median follow-up now is about 18 months. The primary endpoints were OS, PFS, and objective response rates, as assessed by an independent review according to RECIST 1.1 criteria in the intermediate to poor risk IMDC risk group, which is the intent-to-treat (ITT) analysis, while secondary outcomes included the same outcomes in the ITT population of patients. Although the progression-free survival was similar in both arms, the combination of nivolumab-ipilimumab reduced the risk of death by 28% compared to sunitinib in the ITT population of patients. When stratifying the results by IMDC risk groups, the combination arm of nivolumab-ipilimumab showed significant improvement in the intermediate to poor risk group, but there was no difference in the favorable risk group. But in the study, no new safety signals were identified. Dr. Neeraj Agarwal: Thank you, Jeanny, for such a comprehensive description of the results of these two studies. I'd like to add that the median overall survival of patients with metastatic renal cell carcinoma in the ITT population in the CheckMate 214 trial has now reached 53 months, which would have been unimaginable just a decade ago. This is wonderful news for our patients. So the key takeaway from these two abstracts would be that immune checkpoint inhibitor-based combinations remain the backbone of first-line advanced renal cell carcinoma treatment.  Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. This is wonderful news for all of our patients, especially for those who are being treated for first-line therapy.  Now, let's move on to the bladder cancer abstracts. We have two exciting abstracts from the UNITE database. What are your insights on Abstract 537, titled "Outcomes in Patients with Advanced Urethral Carcinoma Treated with Enfortumab Vedotin After Switch-Maintenance of Avelumab in the UNITE Study"? Dr. Neeraj Agarwal: As our listeners know, enfortumab vedotin is an antibody-drug conjugate that binds to a protein called Nectin 4 expressed on bladder cancer cells. In this abstract, Dr. Amanda Nizam and colleagues describe outcomes in 49 patients receiving third-line enfortumab vedotin after prior progression on platinum-based therapy and maintenance avelumab. At a median follow-up of 8.5 months, the median progression-free survival was 7 months and the median overall survival was 13.3 months with enfortumab vedotin in this treatment-refractory setting, the objective response rates were 54%. The message of this study is that enfortumab vedotin is an effective salvage therapy regimen for those patients who have already progressed on earlier lines of therapies, including platinum-based and immunotherapy regimens. Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for that comprehensive review.  I want to focus on another patient population in the UNITE database, which is the use of fibroblast growth factor receptor (FGFR) alterations. Can you tell us more about the sequencing now of erdafitinib and enfortumab vedotin in these patients with metastatic urothelial cancer, as discussed in Abstract 616? Dr. Neeraj Agarwal: Sure, Jeanny. As a reminder, erdafitinib is a fibroblast growth factor receptor kinase inhibitor approved for patients with locally advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 alterations after progression on platinum-based chemotherapy. However, the optimal sequencing of therapies in these patients is unclear, especially with enfortumab vedotin being approved in the salvage therapy setting and now in the frontline therapy setting.  So in this retrospective study, all patients with metastatic urothelial carcinoma had FGFR2 or FGFR3 alterations. Dr. Cindy Jiang and colleagues report outcomes in 24 patients receiving enfortumab vedotin after erdafitinib, 15 patients receiving erdafitinib after enfortumab vedotin, and 55 patients receiving enfortumab vedotin only. This is a multicenter national study. Interestingly, patients receiving both agents had a longer overall survival in a multivariate analysis, regardless of the treatment sequencing, than patients receiving enfortumab vedotin alone or only with a hazard ratio of 0.52. The objective response rate of enfortumab vedotin in the enfortumab vedotin monotherapy arm was 49%. When these agents were sequenced, the objective response with enfortumab vedotin was 32% after erdafitinib and 67% when used before erdafitinib. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. I think these are important real-world data results, but I would like to point out that larger and prospective studies are still needed to confirm these findings, especially regarding the outcome of erdafitinib after enfortumab vedotin, particularly when the latter is used in the first-line setting. Dr. Neeraj Agarwal: I totally agree, Jeanny. Now, let's discuss some abstracts related to disparities in the management of patients with genitourinary cancers.  Dr. Jeanny Aragon-Ching: Sure, actually, I would like to discuss 2 abstracts related to disparities in patients with prostate cancer. So the first one, Abstract 265, titled "Patient-Provider Rurality and Outcomes in Older Men with Prostate Cancer." In this study, Dr. Stabellini, Dr. Guha and the team used a SEER Medicare-linked database that included more than 75,000 patients with prostate cancer. The primary outcome was all-cause mortality, with secondary outcomes included prostate cancer-specific mortality. The investigators showed that the all-cause mortality risk was 44% higher in patients with prostate cancer from rural areas who had a provider from a non-metropolitan area compared to those who were in a metropolitan area and had a provider also from a metropolitan area. Dr. Neeraj Agarwal: Those are very important data and highlight the healthcare disparities among the rural population with prostate cancer that still exist.  So what is your key takeaway from Abstract 267, titled "Rural-Urban Disparities in Prostate Cancer Survival," which is a population-based study? Dr. Jeanny Aragon-Ching: Of course. This abstract discusses, actually, a very similar issue regarding access to healthcare among rural versus urban patients. In this study, Dr. Hu and Hashibe and colleagues and team at the Huntsman Cancer Institute assessed all-cause death and prostate cancer-related death risk in a retrospective study in which patients with prostate cancer based on rural versus urban residencies looked at 18,000 patients diagnosed with prostate cancer between 2004 and 2017. 15% lived in rural counties. Similar to the prior abstract we talked about, patients living in rural areas had about a 19% higher risk of all-cause mortality and a 21% higher risk of prostate cancer-specific mortality in comparison to patients living in urban areas. Dr. Neeraj Agarwal: So Jeanny, we can say that both of these abstracts, led by different groups of investigators, highlight that patients with prostate cancer living in rural areas have inferior survival outcomes compared to those living in urban areas, and it is time to focus on the disparities experienced by the rural population with prostate cancer.  Dr. Jeanny Aragon-Ching: Yeah, absolutely Neeraj. I concur with your thoughts.  So, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Yes, before concluding, Jeanny, I want to express my gratitude for your participation and the valuable insights you have shared today. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today.   As we bring this podcast to a close, I would like to highlight the significant advances happening in the treatment of patients with genitourinary cancers during our upcoming 2024 ASCO GU meeting. Many studies featuring practice-impacting data will be presented by investigators from around the globe. I encourage our listeners to not only participate at this event to celebrate these achievements, but to also play a role in disseminating these cutting-edge findings to practitioners worldwide. By doing so, we can collectively maximize the benefit for patients around the world.  And thank you to our listeners for joining us today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you very much.  Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guest speakers express their own opinions, experience, and conclusions. Guest statements on the podcast do not necessarily reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:     Dr. Neeraj Agarwal  @neerajaiims  Dr. Jeanny Aragon-Ching    Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn       Disclosures:      Dr. Neeraj Agarwal:       Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences    Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas     Dr. Jeanny Aragon-Ching:    Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,   Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics. 

MIB Agents OsteoBites
Focal Adhesion Kinase (FAK) Inhibition to Improve Losartan-Sunitinib Immunotherapy in Metastatic Osteosarcoma

MIB Agents OsteoBites

Play Episode Listen Later Nov 4, 2022 57:07


Dr. Dan Regan discusses his OutSmarting Osteosarcoma funded work on Focal Adhesion Kinase (FAK) inhibition to improve losartan-sunitinib immunotherapy in metastatic osteosarcoma. - Dr. Dan Regan is an Assistant Professor at the Flint Animal Cancer Center at Colorado State University and he is one of our OutSmarting Osteosarcoma 2022 grant recipients. Dr. Regan received his DVM degree from the University of Georgia and subsequently completed his residency training in veterinary anatomic pathology and PhD in the Department of Microbiology, Immunology, and Pathology (MIP) at Colorado State University. In 2018 he joined the Flint Animal Cancer Center and MIP in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. The focus of Dr. Regan's laboratory is to increase our understanding of the interplay between the immune system and (non-immune) tumor stroma, and how these compartments of the tumor microenvironment promote metastasis as well as respond to and mediate extrinsic mechanisms of resistance to anti-cancer therapy. To investigate this area of cancer biology, his laboratory utilizes a combination of in vitro 3-dimensional tumor co-culture models and animal models, focusing on breast and bone cancer (osteosarcoma). Dr. Regan also has a strong interest in comparative oncology and leveraging naturally occurring cancers in dogs as both a surrogate and intermediary model to evaluate and validate his laboratory's investigations into the tumor microenvironment. In collaboration with the laboratory of Dr. Steve Dow, his lab conducted immunotherapy clinical studies in dogs with spontaneous osteosarcoma and these study results have led to a phase I clinical trial in children with osteosarcoma. His lab's continued long-term research goal is to fully elucidate the mechanisms by which tumors prime non-malignant host stromal cells of distant organs to promote their metastasis and chemo-resistance, in order to identify novel targets for host-directed stromal therapies which “poison the soil” for effective combination with conventional tumor cell targeted drugs. --- What We Do at MIB Agents: PROGRAMS: ✨ End-of-Life MISSIONS ✨ Gamer Agents ✨ Agent Writers ✨ Prayer Agents ✨ Healing Hearts - Bereaved Parent Support ✨ Ambassador Agents - Peer Support ✨ Warrior Mail ✨ Young Adult Survivorship Support Group ✨ EDUCATION for physicians, researchers and families: ✨ OsteoBites, weekly webinar & podcast with thought leaders and innovators in Osteosarcoma ✨ MIB Book: Osteosarcoma: From our Families to Yours ✨ RESEARCH: Annual MIB FACTOR Research Conference ✨ Funding $100,000 annually for OS research ✨ MIB Testing & Research Directory ✨ The Osteosarcoma Project partner with Broad Institute of MIT and Harvard ... Kids are still dying with 40+ year old treatments. Help us MakeItBetter.

Medscape InDiscussion: Renal Cell Carcinoma
Non–Clear Cell Renal Cell Carcinoma: A Conversation About Subtypes, Clinical Trials, Treatment Options, and Outcomes

Medscape InDiscussion: Renal Cell Carcinoma

Play Episode Listen Later Oct 4, 2022 20:40


Drs Sumanta Pal and Mehmet Asim Bilen discuss the complexities of treating patients with non–clear cell renal carcinoma, the nuances of rare subtypes, and when to use chemotherapy vs immunotherapy. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968741). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Renal Cell Carcinoma https://emedicine.medscape.com/article/281340-overview Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology https://pubmed.ncbi.nlm.nih.gov/34991070/ PAPMET Trial: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed https://clinicaltrials.gov/ct2/show/NCT02761057 Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates https://ascopubs.org/doi/10.1200/JCO.21.01944 Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605393/ Cabozantinib Plus Nivolumab Phase I Expansion Study in Patients With Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy https://aacrjournals.org/clincancerres/article/28/7/1353/682207/Cabozantinib-plus-Nivolumab-Phase-I-Expansion Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study https://ascopubs.org/doi/10.1200/JCO.21.00939 A Single-Arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma https://pubmed.ncbi.nlm.nih.gov/33867192/ ESMO 2022 https://www.esmo.org/meetings/esmo-immuno-oncology-congress-2022/abstracts Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma. The SAVOIR Phase 3 Randomized Clinical Trial https://jamanetwork.com/journals/jamaoncology/fullarticle/2766797 SAMETA: An Open-Label, Three-Arm, Multicenter, Phase III Study of Savolitinib + Durvalumab Versus Sunitinib and Durvalumab Monotherapy in Patients With MET-Driven, Unresectable, Locally Advanced/Metastatic Papillary Renal Cell Carcinoma (PRCC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.TPS4601 A Phase II Trial of Doxorubicin and Gemcitabine in Renal Cell Carcinoma With Sarcomatoid Features: ECOG 8802 https://pubmed.ncbi.nlm.nih.gov/21298497/ A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) https://clinicaltrials.gov/ct2/show/NCT03141177

Medscape InDiscussion: Renal Cell Carcinoma
Frontline Treatment of Renal Cell Carcinoma

Medscape InDiscussion: Renal Cell Carcinoma

Play Episode Listen Later Sep 1, 2022 20:44


Drs Sumanta Pal and Brian Rini discuss front-line treatment of renal cell carcinoma. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968736). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Bevacizumab Plus Interferon-alpha Versus Interferon-alpha Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206 https://ascopubs.org/doi/10.1200/jco.2009.27.18_suppl.lba5019 An updated table of the front-line IO combination RCC studies that have shown an OS advantage https://twitter.com/brian_rini/status/1309609380585844736/photo/1 Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting https://aacrjournals.org/clincancerres/article/26/9/2087/83102/Targeting-PD-1-or-PD-L1-in-Metastatic-Kidney Conditional Survival and Long-term Efficacy With Nivolumab Plus Ipilimumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34180 International Metastatic Renal Cell Carcinoma Database Consortium Criteria https://www.uptodate.com/contents/image?imageKey=ONC%2F116130&topicKey=ONC%2F2984&source=see_link Molecular Correlates Differentiate Response to Atezolizumab (atezo) + Bevacizumab (bev) vs Sunitinib (sun): Results From a Phase III Study (IMmotion151) in Untreated Metastatic Renal Cell Carcinoma (mRCC) https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/presentation/list?q=LBA31 Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long-term Follow-up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415096/pdf/nihms-1732721.pdf Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma https://www.nejm.org/doi/10.1056/NEJMoa2035716 The Uromigos Debate: Treatment of Favorable Risk Renal Cancer https://anchor.fm/the-uromigos/episodes/Episode-67-The-Third-Uromigos-Debate---fPD1VEGF-vs-PD1CTLA4-for-front-line-renal-cancer-emjpji Health-Related Quality-of-Life Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus Versus Sunitinib (CLEAR): A Randomised, Phase 3 Study https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00212-1/fulltext Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) https://clinicaltrials.gov/ct2/show/NCT03937219 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) https://clinicaltrials.gov/ct2/show/NCT04736706 Twitter poll questions: What magnitude of benefit is required to adopt triplets? OS https://mobile.twitter.com/brian_rini/status/1508450496104783877 What magnitude of absolute PFS benefit vs doublets is required to adopt triplets? https://mobile.twitter.com/brian_rini/status/1508450910506295305 What would be the most convincing endpoint to adopt triplets? https://mobile.twitter.com/brian_rini/status/1508451622564909057 Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436590/ OPtimal Treatment by Invoking biologic Clusters in Renal Cell Carcinoma (OPTIC RCC) https://www.kcameetings.org/wp-content/uploads/2021/12/IKCSNA21_TIP8_Chen.pdf

study trial os treatments phase relevant frontline io checkpoint checkmate clusters invoking randomized rcc pfs medscape pd l1 renal cell carcinoma bevacizumab monotherapy health related quality ipilimumab life outcomes atezolizumab sunitinib everolimus calgb cabozantinib piis1470 lenvatinib
Medscape InDiscussion: Renal Cell Carcinoma
Adjuvant Treatment With Immunotherapy

Medscape InDiscussion: Renal Cell Carcinoma

Play Episode Listen Later Sep 1, 2022 22:37


Drs Sumanta Pal and Tian Zhang review the state of the data on adjuvant treatment with immunotherapy for patients with renal cell carcinoma, including where current clinical trials stand. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/968737). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study https://clinicaltrials.gov/ct2/show/NCT03793166 The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials https://journals.lww.com/journalppo/Abstract/2020/09000/The_Role_of_Targeted_Therapy_in_the_Management_of.3.aspx Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy https://www.nejm.org/doi/10.1056/NEJMoa1611406 Sutent (sunitinib) prescribing information https://labeling.pfizer.com/showlabeling.aspx?id=607 Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (KEYNOTE-564) https://www.nejm.org/doi/full/10.1056/NEJMoa2106391 RAMPART: A Phase III Multi-arm Multi-stage Trial of Adjuvant Checkpoint Inhibitors in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520913/ A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) https://clinicaltrials.gov/ct2/show/NCT03024996 A Comparison of Sunitinib with Cabozantinib, Crizotinib, and Savolitinib for Treatment of Advanced Papillary Renal Cell Carcinoma: a Randomised, Open-Label, Phase 2 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687736/ A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (CheckMate 914) https://clinicaltrials.gov/ct2/show/NCT03138512 PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS4596 Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Results From 30-Month Follow-up of KEYNOTE-564 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.290 Leibovich RCC Model: Prediction of Progression After Radical Nephrectomy for patients With Clear Cell Renal Cell Carcinoma https://cancernomograms.com/nomograms/972 Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results From ASSURE, ECOG 2805 https://aacrjournals.org/clincancerres/article/21/18/4048/117759/Effects-of-Adjuvant-Sorafenib-and-Sunitinib-on

JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patien
Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

JAMA Oncology Author Interviews: Covering research, science, & clinical practice in oncology that improves the care of patien

Play Episode Listen Later Dec 23, 2021 22:38


Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.

JAMA Network
JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

JAMA Network

Play Episode Listen Later Dec 23, 2021 22:38


Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.

CCO Oncology Podcast
Role of TKIs in Nonadipocytic Soft Tissue Sarcoma and Advanced Osteosarcoma

CCO Oncology Podcast

Play Episode Listen Later Nov 2, 2021 18:16


In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and Institute of Cancer ResearchLondon, United KingdomLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq

PODC’AFUF
68. HIGHLIGHT DES NOUVELLES RECOMMANDATIONS 2020 DANS LE CANCER DU REIN DU CCAFU - Pr PIERRE BIGOT

PODC’AFUF

Play Episode Listen Later Dec 30, 2020 6:24


Pr Pierre Bigot : Highlights des recommandations CCAFU 2020-2022 du cancer du reinQuelles sont les messages clés des nouvelles recommandations ? Quelles sont les nouveautés dans la prise en charge chirurgicale du cancer du rein métastatique ? Quelles sont les nouveautés dans le traitement médical de première ligne du cancer du rein métastatique ? Quels messages retenir pour les tumeurs kystiques et les angiomyolipomes sporadiques ?Le Pr Pierre Bigot (CHU d’Angers) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Cet épisode a été réalise grâce au soutien institutionnel des laboratoires IPSENPour aller plus loin :Recommandations françaises du Comité de Cancérologie de l’AFU : actualisation 2020-2022 : prise en charge du cancer du reinhttps://purol-12s.elsevierdigitaledition.com/2/https://www.urofrance.org/outils-et-recommandations/recommandations/recommandations-afu/classees-par-annee.htmlÉtude Carmena :Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3. PMID: 29860937.Etude SURTIME :Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543. Erratum in: JAMA Oncol. 2019 Feb 1;5(2):271. PMID: 30543350; PMCID: PMC6439568.Keynote 426 :Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. PMID: 30779529. Checkmate 214 :Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. Cet épisode a été réalisé grâce au soutien institutionnel des laboratoires IPSEN.Musique du générique : Via AudioNetworkResponsable projet

The Uromigos
Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer

The Uromigos

Play Episode Listen Later Sep 19, 2020 26:12


The group attempts to put the data into context with the other available combinations.

PODC’AFUF
31.CANCER DU REIN MÉTASTATIQUE - Pr ARNAUD MEJEAN

PODC’AFUF

Play Episode Listen Later Jul 1, 2020 7:45


Quel traitement de première ligne proposer pour un cancer du rein métastatique ?Quelle classification pronostique utiliser ? Faut-il encore faire une néphrectomie de cytoréduction ?Quelles sont les dernières actualités dans le cancer du rein métastatique ?Le Pr Arnaud Mejean (Hôpital Européen Georges Pompidou) répond à toutes vos questions !L’orateur n’a pas reçu de rémunération pour la réalisation de cet épisode.Pour aller plus loin :- Lire ici : Méjean A, Ravaud A, Thezenas S, Colas S, Beauval J-B, Bensalah K, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2 août 2018;379(5):417‑27.- Lire ici : Bex A, Mulders P, Jewett M, Wagstaff J, Thienen JV van, Blank CU, et al. Comparisonof Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol. 1 févr 2019;5(2):164‑70.- Lire ici : Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1116‑27.- Lire ici : Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 21 mars 2019;380(12):1103‑15.- Lire ici : otzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 5 avr 2018;378(14):1277‑90.- Lire ici : Recommandations françaises du comité de cancérologie de l’AFU – Actualisation 2020 : Prise en charge du cancer du rein métastatique.Réalisé avec le soutien institutionnel des laboratoires Ipsen.Musique du générique : Via AudioNetworkResponsable projet AFUF : Dr Benjamin PradèreProduction : La Toile Sur Ecoute See acast.com/privacy for privacy and opt-out information.

Plenary Session
2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman

Plenary Session

Play Episode Listen Later Nov 20, 2019 58:22


First up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug. Review of Sunitinib: doi.org/10.1093/jnci/djv292 Benefit, Burden, and Impact: doi.org/10.1177/1740774519873883 Back us on Patreon! www.patreon.com/plenarysession

The ASCO Post Podcast
First-Line Nivolumab and Ipilimumab vs Sunitinib in Advanced Renal Cell Carcinoma

The ASCO Post Podcast

Play Episode Listen Later Sep 5, 2019 13:43


This week, we'll be talking about an extended follow-up of a phase III trial that investigated first-line nivolumab and ipilimumab vs sunitinib in advanced renal cell carcinoma. Then we'll go over a research letter that identified strong predictors of response to immune checkpoint inhibitor treatment. Lastly, we'll review a report on e-cigarette secondhand smoke exposure experienced by middle and high school students.Coverage of stories discussed this week on ascopost.com:Extended Follow-up of CheckMate 214: Nivolumab/Ipilimumab vs Sunitinib as First-Line Treatment for Advanced RCCKey Predictors of Response Rates to PD-1/PD-L1 Inhibitor Therapy Across Cancer TypesExposure to Secondhand E-Cigarette Aerosols Increasing Among Middle and High School Students

Plenary Session
1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola

Plenary Session

Play Episode Listen Later Sep 11, 2018 62:43


In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

The Beacon
Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)

The Beacon

Play Episode Listen Later Aug 10, 2018 2:07


Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC).

2015 Genitourinary Cancers Symposium
Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

2015 Genitourinary Cancers Symposium

Play Episode Listen Later Aug 15, 2017 8:11


Dr Naomi Balzer-Haas talks to ecancertv at ASCO GU 2015 about the initial results from the phase III ASSURE trial. It appears that adjuvant sorafenib or sunitinib do not benefit patients with unfavourable locally advanced renal carcinoma, but these findings raise more questions.

implications renal carcinoma adjuvant asco gu sunitinib sorafenib
SIOG 2014
Older patients benefit from lower doses of sunitinib in renal cell carcinoma

SIOG 2014

Play Episode Listen Later Aug 15, 2017 5:09


"We must dispel this concept of ageism," Dr Kanesvaran tells ecancertv at SIOG 2014. He discusses his study on sunitinib in metastatic renal cell carcinoma, which found that patients benefit from a lower dose. Older patients may particularly benefit from starting treatment at lowered doses.

2015 Genitourinary Cancers Symposium
Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

2015 Genitourinary Cancers Symposium

Play Episode Listen Later Aug 14, 2017 6:02


Prof Figlin talks to ecancertv at ASCO GU 2015 about the use of sunitinib in renal cancer when combined with AGS-003, an autologous immunotherapy designed to induce an immune response to a patient’s own tumour.

2015 Genitourinary Cancers Symposium
Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

2015 Genitourinary Cancers Symposium

Play Episode Listen Later Aug 14, 2017 4:02


Dr Mark Beresford talks to ecancertv at ASCO GU 2015 reflecting on the initial results of the ASSURE trial where adjuvant treatment with sorafenib or sunitinib is used for localised renal carcinoma. Neither sorafenib nor sunitinib provide improved outcomes. Other trials such as SORCE which looks at sorafenib and ATLAS which looks at axitinib question the duration of treatment.

ESMO 2016
Adjuvant sunitinib for renal cell carcinoma

ESMO 2016

Play Episode Listen Later Aug 3, 2017 3:49


Dr Ravaud speaks with ecancertv at ESMO 2016 about results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients. This phase III trial found a longer disease-free survival in the sunitinib arm, and Dr Ravaud describes this extension with the manageable toxicity profile as recommending factors for sunitinib in adjuvant therapy.

ESMO 2016
Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer

ESMO 2016

Play Episode Listen Later Aug 3, 2017 4:08


Dr Ravaud presents, at a press conference at ESMO 2016, results from a one-year trial of sunitinib vs placebo for post-nephrectomy high-risk renal cancer patients. This phase III trial found a longer disease-free survival in the sunitinib arm, and Dr Ravaud describes this extension with the manageable toxicity profile as recommending factors for sunitinib in adjuvant therapy.

ESMO 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma

ESMO 2016

Play Episode Listen Later Aug 3, 2017 6:21


Dr Choueiri presents, at a press conference at ESMO 2016, results of the CABOSUN comparitive trial, which assessed outcomes of patients with metastatic rencal cell carcinoma receiving cabozantinib versus sunitnib. Both drugs are tyrosine kinase inhibitors (TKIs) targeting VEGFR, however cabozantinib has additional actions in inhibition of MET and AXL. He describes the results, which demonstrate improved progression free survival in the cabozantinib arm, and considers its progression towards wider adoption and approval.

metastatic esmo renal cell carcinoma tkis choueiri vegfr sunitinib cabozantinib
Oncology Information Group Podcast
Dr. Eric Jonasch - Alternate Sunitinib Schedule

Oncology Information Group Podcast

Play Episode Listen Later Feb 22, 2017 1:15


alternate sunitinib
Oncology Information Group Podcast
Dr. Eric Jonasch - Alternate Sunitinib Schedule

Oncology Information Group Podcast

Play Episode Listen Later Feb 22, 2017 1:15


alternate sunitinib
GRACEcast
Who Benefits from Immunotherapy?

GRACEcast

Play Episode Listen Later Apr 6, 2015 18:41


Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

benefits therapy cancer immune comprehensive pal monty kidney immunotherapy renal rcc interferon pd l1 nivolumab ipilimumab sunitinib gracecast cancergrace il2 sumanta sumanta monty pal pazopanib immunotherapy forum video interleukin2
GRACEcast ALL Subjects audio and video
Who Benefits from Immunotherapy?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 6, 2015 18:41


Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

benefits therapy cancer immune comprehensive pal monty kidney immunotherapy renal rcc interferon pd l1 nivolumab ipilimumab sunitinib gracecast cancergrace il2 sumanta sumanta monty pal pazopanib immunotherapy forum video interleukin2
GRACEcast Treatments and Support Video
Who Benefits from Immunotherapy?

GRACEcast Treatments and Support Video

Play Episode Listen Later Apr 6, 2015 18:41


Immunotherapy Forum Video #27: Immunotherapies work well in some, but not in others. Who benefits, and why? Dr. Sumanta (Monty) Pal explains what doctors are learning.

benefits therapy cancer immune comprehensive pal monty kidney immunotherapy renal rcc interferon pd l1 nivolumab ipilimumab sunitinib gracecast cancergrace il2 sumanta sumanta monty pal pazopanib immunotherapy forum video interleukin2
GRACEcast ALL Subjects audio and video
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 11, 2015 11:02


Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

GRACEcast
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials

GRACEcast

Play Episode Listen Later Mar 11, 2015 11:02


Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

GRACEcast Kidney Cancer Video
Kidney Cancer Immunotherapy: CTLA-4 & Vaccine Clinical Trials

GRACEcast Kidney Cancer Video

Play Episode Listen Later Mar 11, 2015 11:02


Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 

GRACEcast ALL Subjects audio and video
Immunotherapy Treatments for Kidney Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 19, 2014 3:35


Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.

GRACEcast Kidney Cancer Video
Immunotherapy Treatments for Kidney Cancer

GRACEcast Kidney Cancer Video

Play Episode Listen Later Aug 19, 2014 3:35


Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.

GRACEcast
Immunotherapy Treatments for Kidney Cancer

GRACEcast

Play Episode Listen Later Aug 19, 2014 3:35


Dr. Guru Sonpavde highlights the top research news in immunotherapy for kidney cancer from the ASCO 2014 Annual Meeting.

GRACEcast Kidney Cancer Video
Will Combining Immunotherapies Better Fight Kidney Cancer?

GRACEcast Kidney Cancer Video

Play Episode Listen Later Aug 14, 2014 5:19


Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.

GRACEcast ALL Subjects audio and video
Will Combining Immunotherapies Better Fight Kidney Cancer?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 14, 2014 5:19


Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.

GRACEcast
Will Combining Immunotherapies Better Fight Kidney Cancer?

GRACEcast

Play Episode Listen Later Aug 14, 2014 5:19


Dr. Lauren Harshman discusses what combinations of drugs are being studied in kidney cancer patients.

GRACEcast
No Clear Answer for Non-Clear Cell Kidney Cancer

GRACEcast

Play Episode Listen Later Jul 10, 2014 5:41


Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

cancer md drugs clear pal monty kidney renal asco carcinoma nizar kidney cancer sunitinib everolimus gracecast cancergrace sumanta afinitor sutent
GRACEcast ALL Subjects audio and video
No Clear Answer for Non-Clear Cell Kidney Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 10, 2014 5:41


Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

cancer md drugs clear pal monty kidney renal asco carcinoma nizar kidney cancer sunitinib everolimus gracecast cancergrace sumanta afinitor sutent
GRACEcast Kidney Cancer Video
No Clear Answer for Non-Clear Cell Kidney Cancer

GRACEcast Kidney Cancer Video

Play Episode Listen Later Jul 10, 2014 5:41


Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

cancer md drugs clear pal monty kidney renal asco carcinoma nizar kidney cancer sunitinib everolimus gracecast cancergrace sumanta afinitor sutent
GRACEcast
Treating Newly Diagnosed Kidney Cancer

GRACEcast

Play Episode Listen Later Jul 6, 2014 3:09


Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

GRACEcast Kidney Cancer Video
Treating Newly Diagnosed Kidney Cancer

GRACEcast Kidney Cancer Video

Play Episode Listen Later Jul 6, 2014 3:09


Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

GRACEcast ALL Subjects audio and video
Treating Newly Diagnosed Kidney Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 6, 2014 3:09


Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

GRACEcast
Maintenance Therapy in Small Cell Lung Cancer

GRACEcast

Play Episode Listen Later Apr 17, 2014 1:53


Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

GRACEcast ALL Subjects audio and video
Maintenance Therapy in Small Cell Lung Cancer

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Apr 17, 2014 1:53


Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

GRACEcast Lung Cancer Video
Maintenance Therapy in Small Cell Lung Cancer

GRACEcast Lung Cancer Video

Play Episode Listen Later Apr 17, 2014 1:53


Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

GRACEcast Lung Cancer Audio
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Aug 16, 2013 4:08


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 16, 2013 4:08


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

GRACEcast Lung Cancer Video
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Aug 16, 2013 4:09


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

GRACEcast ALL Subjects audio and video
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Aug 16, 2013 4:09


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

GRACEcast
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (audio)

GRACEcast

Play Episode Listen Later Aug 16, 2013 4:08


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

GRACEcast
ASCO Lung Cancer Highlights, Part 7: Maintenance Therapy for Small Cell Lung Cancer? (video)

GRACEcast

Play Episode Listen Later Aug 16, 2013 4:09


Dr. David Gerber, University of Texas-Southwestern, discusses the key results and potential implications of the CALGB 30504 trial of maintenance sunitinib for extensive stage SCLC.

Gastrointestinal Stromal Tumor (GIST) Summit - Video
GIST Treatment After Imatinib & Sunitinib: Other Drugs

Gastrointestinal Stromal Tumor (GIST) Summit - Video

Play Episode Listen Later Oct 24, 2010 12:21


drugs treatments gist sunitinib imatinib
Medizin - Open Access LMU - Teil 16/22
Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy

Medizin - Open Access LMU - Teil 16/22

Play Episode Listen Later Jan 1, 2010


A 74-year-old man with metastatic renal cell carcinoma and a history of cardiac failure was treated with sunitinib malate. MUGA echocardiography could not detect a relevant change in the ejection fraction although the clinical situation of the patient worsened dramatically. The only parameter to hint at the deteriorated cardiac function was plasma N-terminal pro-brain natriuretic peptide (BNP). Finally, the patient died after only one cycle of sunitinib treatment. We propose to prospectively include BNP for the early detection of cardiovascular decompensation in high-risk patients. Future studies concerning the relevance of BNP in drug-related cardiotoxicity are urgently needed. Copyright (C) 2010 S. Karger AG, Basel

Oncology Times Broadcast News
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival

Oncology Times Broadcast News

Play Episode Listen Later Sep 28, 2009 4:37


Oncology Times Broadcast News: Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival Treatment of advanced pancreatic islet cell tumors with sunitinib has doubled progression-free survival in patients whose options have been very limited up to now, according to French researchers reporting their phase III randomized study findings at the World Congress on Gastrointestinal Cancer in Barcelona (24-27 June, 2009; ABSTRACT: 0-0013). Eric Raymond from Beaujon University Hospital, Villejuif, France, gave Peter Goodwin his clinical interpretation of the findings.

Oncology Times - OT Broadcasts from the iPad Archives
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study

Oncology Times - OT Broadcasts from the iPad Archives

Play Episode Listen Later Sep 2, 2009 4:37


Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer

OT Broadcast News
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study

OT Broadcast News

Play Episode Listen Later Aug 14, 2009 4:37


Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer

The Lancet Oncology
The Lancet Oncology: July 29, 2009

The Lancet Oncology

Play Episode Listen Later Jul 29, 2009 5:46


Rob Brierley discusses sunitinib for kidney cancer, and how bureaucracy is stifling UK clinical research.